Literature DB >> 30335906

Phenotypic Prioritization of Diphyllin Derivatives That Block Filoviral Cell Entry by Vacuolar (H+ )-ATPase Inhibition.

Aaron Lindstrom1, Manu Anantpadma2,3, Logan Baker1, N M Raghavendra1, Robert Davey2,3, Vincent Jo Davisson1.   

Abstract

Many viruses use endosomal pathways to gain entry into cells and propagate infection. Sensing of endosomal acidification is a trigger for the release of many virus cores into the cell cytosol. Previous efforts with inhibitors of vacuolar ATPase have been shown to block endosomal acidification and affect viral entry, albeit with limited potential for therapeutic selectivity. In this study, four novel series of derivatives of the vacuolar ATPase inhibitor diphyllin were synthesized to assess their potential for enhancing potency and anti-filoviral activity over cytotoxicity. Derivatives that suitably blocked cellular entry of Ebola pseudotyped virus were further evaluated as inhibitors of endosomal acidification and isolated human vacuolar ATPase activity. Several compounds with significant increases in potency over diphyllin in these assays also separated from cytotoxic doses in human cell models by >100-fold. Finally, three derivatives were shown to be inhibitors of replication-competent Ebola viral entry into primary macrophages with similar potencies and enhanced selectivity toward antiviral activity.
© 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Ebolavirus inhibitors; antiviral agents; diphyllin; phenotypic screening; vacuolar ATPase

Mesh:

Substances:

Year:  2018        PMID: 30335906      PMCID: PMC6387451          DOI: 10.1002/cmdc.201800587

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  42 in total

Review 1.  Vacuolar H(+)-ATPases. Targets for drug discovery?

Authors:  D J Keeling; M Herslöf; B Ryberg; S Sjögren; L Sölvell
Journal:  Ann N Y Acad Sci       Date:  1997-11-03       Impact factor: 5.691

2.  Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay.

Authors:  Hatem A Elshabrawy; Jilao Fan; Christine S Haddad; Kiira Ratia; Christopher C Broder; Michael Caffrey; Bellur S Prabhakar
Journal:  J Virol       Date:  2014-02-05       Impact factor: 5.103

3.  mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase.

Authors:  Roberto Zoncu; Liron Bar-Peled; Alejo Efeyan; Shuyu Wang; Yasemin Sancak; David M Sabatini
Journal:  Science       Date:  2011-11-04       Impact factor: 47.728

Review 4.  Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus.

Authors:  Ilhem Messaoudi; Gaya K Amarasinghe; Christopher F Basler
Journal:  Nat Rev Microbiol       Date:  2015-10-06       Impact factor: 60.633

5.  Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection.

Authors:  Kartik Chandran; Nancy J Sullivan; Ute Felbor; Sean P Whelan; James M Cunningham
Journal:  Science       Date:  2005-04-14       Impact factor: 47.728

6.  Novel Small Molecule Entry Inhibitors of Ebola Virus.

Authors:  Arnab Basu; Debra M Mills; Daniel Mitchell; Esther Ndungo; John D Williams; Andrew S Herbert; John M Dye; Donald T Moir; Kartik Chandran; Jean L Patterson; Lijun Rong; Terry L Bowlin
Journal:  J Infect Dis       Date:  2015-07-22       Impact factor: 5.226

7.  Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs.

Authors:  Jennifer Kouznetsova; Wei Sun; Carles Martínez-Romero; Gregory Tawa; Paul Shinn; Catherine Z Chen; Aaron Schimmer; Philip Sanderson; John C McKew; Wei Zheng; Adolfo García-Sastre
Journal:  Emerg Microbes Infect       Date:  2014-12-17       Impact factor: 7.163

8.  SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules.

Authors:  Antoine Daina; Olivier Michielin; Vincent Zoete
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

9.  Flex-nucleoside analogues - Novel therapeutics against filoviruses.

Authors:  Mary K Yates; Mithun R Raje; Payel Chatterjee; Christina F Spiropoulou; Sina Bavari; Mike Flint; Veronica Soloveva; Katherine L Seley-Radtke
Journal:  Bioorg Med Chem Lett       Date:  2017-04-22       Impact factor: 2.823

10.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.

Authors:  Xiangguo Qiu; Gary Wong; Jonathan Audet; Alexander Bello; Lisa Fernando; Judie B Alimonti; Hugues Fausther-Bovendo; Haiyan Wei; Jenna Aviles; Ernie Hiatt; Ashley Johnson; Josh Morton; Kelsi Swope; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Michael H Pauly; Jesus Velasco; James Pettitt; Gene G Olinger; Kevin Whaley; Bianli Xu; James E Strong; Larry Zeitlin; Gary P Kobinger
Journal:  Nature       Date:  2014-08-29       Impact factor: 49.962

View more
  3 in total

Review 1.  Ebola Virus Entry: From Molecular Characterization to Drug Discovery.

Authors:  Cristiano Salata; Arianna Calistri; Gualtiero Alvisi; Michele Celestino; Cristina Parolin; Giorgio Palù
Journal:  Viruses       Date:  2019-03-19       Impact factor: 5.048

2.  Oxidative stress protein Oxr1 promotes V-ATPase holoenzyme disassembly in catalytic activity-independent manner.

Authors:  Md Murad Khan; Seowon Lee; Sergio Couoh-Cardel; Rebecca A Oot; Hyunmin Kim; Stephan Wilkens; Soung-Hun Roh
Journal:  EMBO J       Date:  2021-12-17       Impact factor: 14.012

3.  Evaluation of Phenol-Substituted Diphyllin Derivatives as Selective Antagonists for Ebola Virus Entry.

Authors:  Caroline B Plescia; Aaron R Lindstrom; Maritza V Quintero; Patrick Keiser; Manu Anantpadma; Robert Davey; Robert V Stahelin; V Jo Davisson
Journal:  ACS Infect Dis       Date:  2022-03-31       Impact factor: 5.578

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.